Mylan’s Stock Jumps After $465 Million EpiPen Settlement
- Shares rise as much as 13%, rebound from three-year low
- Company also gets inquiry from SEC asking about Medicaid
Mylan NV's EpiPen allergy shots sit on display for a photograph in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016.
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
Mylan NV climbed as much as 13 percent after the drugmaker agreed to pay the U.S. government $465 million in a swift settlement over how it charged Medicaid for its allergy shot EpiPen.
The stock was up 10 percent to $39.47 at 9:42 a.m. in New York, rebounding from a three-year-low at the close Friday.